BRPI0815743A2 - Proteínas hiv env com modificações no laço v3 - Google Patents

Proteínas hiv env com modificações no laço v3

Info

Publication number
BRPI0815743A2
BRPI0815743A2 BRPI0815743-0A2A BRPI0815743A BRPI0815743A2 BR PI0815743 A2 BRPI0815743 A2 BR PI0815743A2 BR PI0815743 A BRPI0815743 A BR PI0815743A BR PI0815743 A2 BRPI0815743 A2 BR PI0815743A2
Authority
BR
Brazil
Prior art keywords
hiv env
env proteins
loop modifications
loop
modifications
Prior art date
Application number
BRPI0815743-0A2A
Other languages
English (en)
Inventor
Susan W Barnett
Ying Lian
Victoria Sharma
Indresh K Srivastava
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0815743A2 publication Critical patent/BRPI0815743A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
BRPI0815743-0A2A 2007-08-24 2008-08-25 Proteínas hiv env com modificações no laço v3 BRPI0815743A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96604807P 2007-08-24 2007-08-24
PCT/US2008/074179 WO2009029569A1 (en) 2007-08-24 2008-08-25 Hiv env proteins with modifications in the v3 loop

Publications (1)

Publication Number Publication Date
BRPI0815743A2 true BRPI0815743A2 (pt) 2015-02-18

Family

ID=39884817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815743-0A2A BRPI0815743A2 (pt) 2007-08-24 2008-08-25 Proteínas hiv env com modificações no laço v3

Country Status (5)

Country Link
EP (1) EP2192918A1 (pt)
JP (1) JP2010536885A (pt)
BR (1) BRPI0815743A2 (pt)
CA (1) CA2697370A1 (pt)
WO (1) WO2009029569A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013279456A1 (en) * 2012-06-18 2014-12-18 Glaxosmithkline Biologicals Sa Stabilized gp120

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3928593A (en) * 1992-04-01 1993-11-08 Merck & Co., Inc. Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
CA2386499A1 (en) * 1999-10-05 2001-04-12 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2003091275A2 (en) * 2002-04-23 2003-11-06 Andrea Savarino Compositions containing anti-hiv peptides and methods of use
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them

Also Published As

Publication number Publication date
CA2697370A1 (en) 2009-03-05
WO2009029569A1 (en) 2009-03-05
JP2010536885A (ja) 2010-12-02
EP2192918A1 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
NL301082I2 (nl) luspatercept
DK3335728T3 (da) Biokemisk stabiliseret hiv-1 env-trimervaccine
ATE450271T1 (de) Impfstoff
DE602007010203D1 (de) Kombinierte Energiestufentaste
DK2004632T3 (da) Hiv-inhiberende 5-amidosubstituerede pyrimidiner
BRPI0917773A2 (pt) "membro antiviral"
DK3118221T3 (da) Proteiner
BRPI0911308A2 (pt) anel gástrico com bolsas oscilantes
BRPI0916763A2 (pt) dialisador
BRPI0918823A2 (pt) beta-glicosidases modificadas com estabilidades aperfeicoada
BRPI0812075A2 (pt) Paletes com balança
DK2125048T3 (da) Præparat
BRPI0916129A2 (pt) "reforço"
DK1989220T3 (da) HIV-fusionsinhibitorpeptider med forbedrede biologiske egenskaber
DE602007007755D1 (de) Fußplatte
FR22C1045I2 (fr) Conjugués protéine-polymère
BRPI0912133A2 (pt) artigo resitente á penetração, e, uso do mesmo.
EP2217270A4 (en) ANTIGEN-ANTIBODY COMPLEXES AS VACCINES AGAINST HIV-1
DK1877549T3 (da) HIV-vaccine
BRPI0815743A2 (pt) Proteínas hiv env com modificações no laço v3
SE0701400L (sv) Odlingssystem
ATE488416T1 (de) Bob
DE502007000429D1 (de) Kinderhochstuhl
NO20091452L (no) Mottakerorientering
FI8011U1 (fi) Heijastin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.